Clinical trials: Interstitial Pulmonary Fibrosis
Asthma, Chronic Obstructive Pulmonary Disease
Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease
This is a single centre exploratory study that aims to apply hyperpolarized xenon-129 (129Xe) magnetic resonance imaging (MRI) methods and measurements in individual patients with and without lung disease to better understand…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Bronchiectasis, Emphysema
- Trial name
- NCT03455686
- Testing
- Hyperpolarized 129Xe MRI
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McMaster University
Severe Acute Respiratory Syndrome Coronavirus 2, Acute Respiratory Distress Syndrome
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), an emerging coronavirus, which has already infected 192 million people with a case fatality rate close to 2%.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
- Trial name
- FIBRO-COVID (NCT04987528)
- Testing
- Aminoterminal type III peptide of procollagen, Lung computed tomography
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hôpital Européen Marseille
Chronic Lung Diseases, COPD
Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease
The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.
- Conditions
- Chronic Lung Diseases, COPD, Pulmonary Fibrosis
- Trial name
- NCT00911794
- Testing
- Disclosure Writing (Written Disclosure Therapy)
- Volunteers
- 66 people
- Sponsor
- Winthrop University Hospital
Idiopathic Pulmonary Fibrosis
ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution
Idiopathic pulmonary fibrosis (IPF) is one of the most common chronic idiopathic fibrotic interstitial lung disease (ILD). IPF is an evolving disease that requires regular follow-up through clinical examination, respiratory…
- Trial name
- TOUPIE (NCT03944928)
- Testing
- Lung ultrasound
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Tours
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA2 (NCT03733444)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Argentina and 13 more
- Volunteers
- 781 people
- Sponsor
- Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis (IPF)
Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Nintedanib combined with or without Dextromethorphan for the treatment of IPF, with FVC as the primary efficacy endpoint to evaluate its effectivenes.
- Trial name
- NCT07583589
- Testing
- Nintedanib,Dextromethorphan
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).
- Trial name
- NCT00080223
- Testing
- Pirfenidone
- Where
- 27 sites in United States
- Volunteers
- 83 people
- Sponsor
- Genentech, Inc.